PharmaMar’s Aplidin Back On EMA’s Agenda After Conflict Of Interest Controversy

The European Medicines Agency is re-evaluating the marketing application for Aplidin. The initial application was rejected in 2018, but that rejection was revoked last year following a court case for another company’s drug that clarified impartiality requirements for experts consulted by the EMA.